Why the study?
Does preoperative levosimendan improve hemodynamics in a heart failure patient undergoing thoracic surgery?
Does preoperative levosimendan improve hemodynamics in a heart failure patient undergoing thoracic surgery?
Prophylactic preoperative levosimendan administration may be safe and effective for optimizing hemodynamics in severe heart failure patients undergoing thoracic surgery.
Answers are grounded in this paper and cite their sources.
Levosimendan may aid procedural tolerance in end-stage HF; hypothesis-generating and requires prospective validation before any practice consideration.
INTRODUCTION: We present the case of a patient with dilatative cardiomyopathy waiting for heart transplantation with pleural effusion to be subjected to pleural biopsy, treated with preoperative infusion of levosimendan to improve heart performances. PRESENTATION OF CASE: A 56-year-old man (BMI 22,49) with dilatative cardiomyopathy (EF 18%) presented right pleural effusion. The levosimendan treatment protocol consisted of 24h continuous infusion (0,1ug/kg/min), without bolus. The patient was under continuous hemodynamic monitoring prior, during and after levosimendan administration. The surgery for pleural biopsy was performed with uniportal Video Assisted Thoracoscopic approach (VATS). DISCUSSION: A significant increase of Cardiac Index (CI) and Stroke Volume Index (SVI) were observed at 4h after infusion initiation and was sustained during the next 24h after the end of infusion. Levosimendan administration was safe. CONCLUSION: In this case the prophylactic preoperative levosimendan administration is safe and effective in cardiac failure patient undergoing thoracic surgery, but prophylactic preoperative levosimendan treatment in these patients merits further study.
No takes yet. Share an insight, caveat, or question.
Nespoli et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: